uniQure, CSL claim first okay for hemophilia B gene therapy

uniQure and CSL have become the first pharma companies to get regulatory approval for a gene therapy for hemophilia B anywhere in the world, after the FDA cleared their Hemgenix therapy for adults with the bleeding disorder in the US.